脂蛋白a在脑血管病中的研究新进展

doi:10.3969/j.issn.1006-7795.2025.01.012

摘要/Abstract

摘要： 脂蛋白a［lipoprotein (a)，Lp(a)］是血浆中一种具有特殊结构的脂蛋白颗粒。Lp(a)浓度升高与多种脑血管疾病密切相关，且多种靶向降低 Lp(a)浓度的新型药物正处于临床试验阶段。本文综述了Lp(a)的结构、功能、遗传学特点、与脑血管病的相关性及其治疗的最新进展，旨在为Lp(a)的研究提供新方向，并为脑血管病的防治提供新思路。

关键词: 脂蛋白a, 脑血管病, 临床研究进展, RNA靶向治疗

Abstract: Lipoprotein(a)［Lp(a)］ is a unique plasma lipoprotein particle with a distinct structure that has garnered significant research attention due to its strong association with various cerebrovascular diseases. Recent studies underscore elevated Lp(a) levels as a critical risk factor, with multiple Lp(a)-targeted therapies advancing through clinical trials. This review explores the structural, functional, and genetic features of Lp(a), its connection to cerebrovascular diseases, and the latest therapeutic strategies aimed at reducing its impact. By consolidating these advancements, we aim to provide new insights for Lp(a)-centered research and propose innovative approaches for cerebrovascular disease prevention and management.

Key words: lipoprotein(a), cerebrovascular diseases, RNA-targeted therapies, advances in clinical studies

中图分类号:

R743

郭怡兵, 孟然. 脂蛋白a在脑血管病中的研究新进展[J]. 首都医科大学学报, 2025, 46(1): 71-75.

Guo Yibing, Meng Ran. Research advances on lipoprotein(a) in cerebrovascular diseases[J]. Journal of Capital Medical University, 2025, 46(1): 71-75.

参考文献

［1］ Arnold M, Schweizer J, Nakas C T, et al. Lipoprotein(a)is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study［J］. Eur Heart J, 2021, 42(22): 2186－2196.
［2］ Berg K. A new serum type system in man-the LP system［J］. Acta Pathol Microbiol Scand, 1963, 59: 369－382.
［3］ Konrad S, Asma N , Florian K , Gerd U, et al. Structure, function, and genetics of lipoprotein (a)［J］. J Lipid Res, 2016, 57(8):1339-1359.
［4］ Clarke R, Peden J F, Hopewell J C, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease［J］. N Engl J Med, 2009, 361(26): 2518－2528.
［5］ Kim B J, Lee M Y, Choi H I, et al. Lipoprotein(a)-related cardiovascular and all-cause mortalities in Korean adults［J］. Eur J Prev Cardiol, 2023, 30(4): 308－317.
［6］ Lin L J, Deng K Q, Chen Z, et al. Lipoprotein(a) distribution and its association with carotid arteriopathy in the Chinese population［J］. Atherosclerosis, 2023, 372: 1－9.
［7］ Guan W H, Cao J, Steffen B T, et al. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis［J］. Arterioscler Thromb Vasc Biol, 2015, 35(4): 996－1001.
［8］ Kiechl S, Willeit J. The mysteries of lipoprotein(a)and cardiovascular disease revisited［J］. J Am Coll Cardiol, 2010, 55(19): 2168－2170.
［9］ Labudovic D, Kostovska I, Tosheska T K, et al. Lipoprotein(a)-link between atherogenesis and thrombosis［J］. Prague Med Rep, 2019, 120(2/3): 39－51.
［10］ Etingin O R, Hajjar D P, Hajjar K A, et al. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis［J］. J Biol Chem, 1991, 266(4):2459-2465.
［11］ Pan S, Kleppe L S, Witt T A, et al. The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis［J］. Thromb Haemost, 2004, 92(3): 495－502.
［12］ van der Valk F M, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans［J］. Circulation, 2016, 134(8): 611－624.
［13］ Tsimikas S, Witztum J L. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity［J］. Curr Opin Lipidol, 2008, 19(4): 369－377.
［14］ Stefanadis C, Antoniou C K, Tsiachris D, et al. Coronary atherosclerotic vulnerable plaque: current perspectives［J］. J Am Heart Assoc, 2017, 6(3): e005543.
［15］ Duan Y, Zhao D, Sun J, et al. Lipoprotein(a) is associated with the progression and vulnerability of new-onset carotid atherosclerotic plaque［J］. Stroke, 2023, 54(5): 1312－1319.
［16］ van Dam-Nolen D H K, van Dijk A C, Crombag G A J C, et al. Lipoprotein(a) levels and atherosclerotic plaque characteristics in the carotid artery: the Plaque at RISK (PARISK) study［J］. Atherosclerosis, 2021, 329: 22－29.
［17］ Xia S, Qiu W D, Cai A P, et al. The association of lipoprotein(a) and intraplaque neovascularization in patients with carotid stenosis: a retrospective study［J］. BMC Cardiovasc Disord, 2021, 21(1): 285.
［18］ Feigin V L, Brainin M, Norrving B, et al. World Stroke Organization (WSO): global stroke fact sheet 2022［J］. Int J Stroke, 2022, 17(1): 18－29.
［19］ Langsted A, Nordestgaard B G, Lipoprotein K P . Elevated lipoprotein(a) and risk of ischemic stroke［J］. J Am Coll Cardiol, 2019, 74(1): 54－66.
［20］ Pan Y S, Li H, Wang Y L, et al. Causal effect of Lp(a)［lipoprotein(a)］ level on ischemic stroke and alzheimer disease: a mendelian randomization study［J］. Stroke, 2019, 50(12): 3532－3539.
［21］ Arora P, Kalra R, Callas P W, et al. Lipoprotein(a) and risk of ischemic stroke in the REGARDS study［J］. Arterioscler Thromb Vasc Biol, 2019, 39(4): 810－818.
［22］ Lackova A, Gdovinova Z, Kozarova M, et al. Lipoprotein (a) concentration as a risk factor for ischaemic stroke and its subtypes［J］. Neurol Neurochir Pol, 2024, 58(3): 316－322.
［23］ Rudin S, Kriemler L, Dittrich T D, et al. Lipoprotein(a) as a blood marker for large artery atherosclerosis stroke etiology: validation in a prospective cohort from a Swiss stroke center［J］. Swiss Med Wkly, 2024, 154: 3633.
［24］ Mohammadi-Shemirani P, Chong M, Narula S, et al. Elevated lipoprotein(a) and risk of atrial fibrillation: an observational and mendelian randomization study［J］. J Am Coll Cardiol, 2022, 79(16): 1579－1590.
［25］ Guo J C, Zhou Y, Zhou B F. Development and validation of a new nomogram model for predicting acute Ischemic stroke in elderly patients with non-valvular atrial fibrillation: a single-center cross-sectional study［J］. Clin Interv Aging, 2024, 19:67-79.
［26］ Feng Z, Xu J, Jin A, et al. Elevated homocysteine intensify the effect of lipoprotein(a)on stroke recurrence［J］. J Am Heart Assoc, 2023, 12(1): e026707.
［27］ Xu J, Hao X W, Zhan R, et al. Effect of lipoprotein(a) on stroke recurrence attenuates at low LDL-C (low-density lipoprotein) and inflammation levels［J］. Stroke, 2022, 53(8): 2504－2511.
［28］ Dong W, Zhong X, Yuan K, et al. Lipoprotein(a)and functional outcome of acute ischemic stroke when discordant with low density lipoprotein-cholesterol［J］. Postgrad Med J, 2023, 99(1177): 1160－1166.
［29］ Skuza A A, Polak M, Undas A. Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties［J］. J Thromb Thrombolysis, 2019, 47(1): 8－15.
［30］ Kronenberg F, Mora S, Stroes E S G, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement［J］. Eur Heart J, 2022, 43(39): 3925－3946.
［31］ Pearson G J, Thanassoulis G, Anderson T J, et al. 2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults［J］. Can J Cardiol, 2021, 37(8): 1129－1150.
［32］ Safarova M S, Moriarty P M. Lipoprotein apheresis: current recommendations for treating familial hypercholesterolemia and elevated lipoprotein(a)［J］. Curr Atheroscler Rep, 2023, 25(7):391-404.
［33］ Sahebkar A, Reiner Ž, Simental-Mendía L E, et al. Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials［J］. Metabolism, 2016, 65(11): 1664－1678.
［34］ Sahebkar A, Serban M C, Penson P, et al. The effects of tamoxifen on plasma lipoprotein(a) concentrations: systematic review and Meta-analysis［J］. Drugs, 2017, 77(11): 1187－1197.
［35］ Alkhalil M. Lipoprotein(a) reduction in persons with cardiovascular disease［J］. N Engl J Med, 2020, 382(21): e65.
［36］ O'Donoghue M L, Rosenson R S, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a)in cardiovascular disease［J］. N Engl J Med, 2022, 387(20): 1855－1864.
［37］ Diaz N, Perez C, Escribano A M, et al. Discovery of potent small-molecule inhibitors of lipoprotein(a)formation［J］. Nature, 2024, 629(8013): 945－950.
［38］ Nicholls S J, Nissen S E, Fleming C, et al. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial［J］. JAMA, 2023, 330(11): 1042－1053.
［39］ Gaudet D, Watts G F, Robinson J G, et al. Effect of alirocumab on lipoprotein(a) over ≥1.5 years (from the phase 3 ODYSSEY program)［J］. Am J Cardiol, 2017, 119(1): 40－46.
［40］ Watts G F, Chan D C, Somaratne R, et al. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics［J］. Eur Heart J, 2018, 39(27): 2577－2585.
［41］ O'Donoghue M L, Fazio S, Giugliano R P, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk［J］. Circulation, 2019, 139(12): 1483－1492.
［42］ Curry W T J, Butler W E, Barker F G 2. Rapidly rising incidence of cerebrospinal fluid shunting procedures for idiopathic intracranial hypertension in the United States, 1988－2002［J］. Neurosurgery, 2005, 57(1): 97－108; discussion 97－108.

[1]	杨笑, 孟媛媛, 杨靖仪, 王书函, 张立功. 血浆致动脉粥样硬化指数、三酰甘油－葡萄糖指数、脑小血管病影像学标志物对急性缺血性脑卒中患者静脉溶栓早期神经功能恢复的预测价值 [J]. 首都医科大学学报, 0, (): 48-55.
[2]	张萌, 马咏馨, 贾琼, 张东威, 张昕红, 徐耀铭. 静脉溶栓治疗急性轻型非致残性缺血性脑卒中有效性和安全性的临床观察：一项单中心回顾性观察研究[J]. 首都医科大学学报, 2025, 46(1): 56-62.
[3]	刘肖朦, 周绍娟, 邵小红, 徐文平, 宦峰, 朱向阳. 南通市医防协同管理模式下脑卒中现状及四级预防[J]. 首都医科大学学报, 2025, 46(1): 63-67.
[4]	乔玥, 李传辉, 赵文博. 急性缺血性脑卒中的再灌注治疗的现状与未来[J]. 首都医科大学学报, 2025, 46(1): 68-70.
[5]	崔玮, 庞淇丹, 相韩悦, 肖猱, 姜德春, 李深, 沈光莉. 利用BIBP-H荧光探针进行脑缺血再灌注损伤检测[J]. 首都医科大学学报, 2025, 46(1): 76-82.
[6]	国家卫生健康委加强脑卒中防治工作减少百万新发残疾工程专家委员会, 吉训明. 推进国家卫生健康委加强脑卒中防治工作减少百万新发残疾工程：中国脑卒中防治现状与战略[J]. 首都医科大学学报, 2025, 46(1): 11-14.
[7]	亚•娜仁, 刘闫, 周霞, 朱德坤, 陈枫, 马争飞, 李传辉, 孙中武. 视网膜中央动脉阻塞患者脑血管造影特征分析及预后研究[J]. 首都医科大学学报, 2025, 46(1): 15-21.
[8]	褚学红, 申英杰, 王耀楼, 董晓, 刘圆圆, 冯艳, 姜缪文, 李明, 吉训明, 吴川杰. 基于孟德尔随机化探索广泛的血管周围间隙负荷与缺血性卒中及其亚型和短暂性脑缺血发作的因果关系[J]. 首都医科大学学报, 2025, 46(1): 22-33.
[9]	王银平, 孟灿灿, 吴文娟, 杨直堂. CD62P、CD40L及节律核受体Rev-erbα在缺血性脑卒中不同发病时间的表达[J]. 首都医科大学学报, 2025, 46(1): 34-40.
[10]	詹艳丽, 李一吟, 李平, 孙景萍, 黄良通, 蔡学礼. 基于区域卒中分级诊疗网络救治急性缺血性脑卒中的现状及疗效分析[J]. 首都医科大学学报, 2025, 46(1): 41-47.
[11]	安琪, 杨楠, 朱玥荃, 师文娟, 黄敏琪, 赵咏梅. 自噬抑制剂3-MA对脑缺血再灌注损伤大鼠脑内炎症反应的影响[J]. 首都医科大学学报, 2024, 45(6): 1008-1015.
[12]	李亚堃, 李蔚, 杨雪琦, 师文娟, 朱玥荃, 赵咏梅. 活性氧自由基清除剂EUK-134对脑缺血再灌注损伤大鼠线粒体相关蛋白PGC-1α和VDAC1的影响[J]. 首都医科大学学报, 2024, 45(6): 1016-1022.
[13]	刘扬, 高超, 王小杰, 张梁, 吴安石. 瑞马唑仑和丙泊酚麻醉对脑血管内手术的老年患者术后谵妄的影响[J]. 首都医科大学学报, 2024, 45(6): 1023-1028.
[14]	李兴茂, 李秀, 王婷, 赵鑫, 王德杨, 商海燕, 赵咏梅, 李森. GLP-1 受体激动剂对 2 型糖尿病患者急性缺血性脑卒中后认知功能的影响[J]. 首都医科大学学报, 2024, 45(6): 1029-1037.
[15]	沈童, 李芳芳, 范俊芬, 罗玉敏. 外周血Yes相关蛋白与缺血性卒中预后影响因素及卒中后炎性反应指标的相关性分析[J]. 首都医科大学学报, 2024, 45(6): 1071-1078.